Persistent expression of high-risk HPV oncogenes is necessary for the development of anogenital and 11 oropharyngeal cancers. Here, we show that E6/E7 expressing cells are hypersensitive to DNA 12 crosslinking agent cisplatin and have defects in repairing DNA interstrand crosslinks (ICL). Importantly, 13 we elucidate how E6/E7 attenuate the Fanconi anemia (FA) DNA crosslink repair pathway. Though 14 E6/E7 activated the pathway by increasing FancD2 monoubiquitination and foci formation, they inhibited 15 the completion of the repair by multiple mechanisms. E6/E7 impaired FancD2 colocalization with double-16 strand breaks (DSB), which subsequently hindered the recruitment of downstream protein Rad51 to DSB 17 in E6 cells. Further, E6 expression caused delayed FancD2 de-ubiquitination, an important process for 18 effective ICL repair. Delayed FancD2 de-ubiquitination was attributed to the increased chromatin 19 retention of FancD2 hindering USP1 de-ubiquitinating activity, and persistently activated ATR/CHK-20 1/pS565 FancI signaling. E6 mediated p53 degradation did not hamper the cell cycle specific process of 21 FancD2 modifications but abrogated repair by disrupting FancD2 de-ubiquitination. Further, E6 reduced 22 the expression and foci formation of Palb2, which is a repair protein downstream of FancD2. These 23 findings uncover unique mechanisms by which HPV oncogenes contribute to genomic instability and the 24 response to cisplatin therapies. 25 42 High-risk human papillomavirus (HR-HPV) E6/E7 oncoproteins are essential for the development of 43 malignancies of the anogenital tract and oropharynx, with HPV16 being the predominant type (1). 44 Cervical and oropharyngeal cancers are the most common HPV-associated malignancies among females 45 and males, respectively (2). Persistent HPV infection destabilizes the cellular genome which can lead to 46 cancer. Genomic instability is likely the result of the numerous interactions of HPV oncoproteins with 47 host tumor suppressors and DNA damage repair (DDR) proteins. Recently, we demonstrated that high-48 risk HPV oncogenes attenuate double-strand break (DSB) repair by impairing the homologous 49 recombination pathway (3). To further elucidate the mechanisms by which HPV oncogenes impair DDR, 50 the present study focuses on the impact of HPV16 oncogenes on the Fanconi anemia-BRCA (FA or FA-51 BRCA) pathway.
26
AUTHOR SUMMARY
27
High-risk human papillomavirus (HPV) causes nearly all cervical and many other anogenital cancers, and 28 oropharyngeal cancers. As cisplatin is the most commonly used drug for cervical and HPV-associated 29 oropharyngeal cancers, it is important to understand how HPV oncogenes disrupt the Fanconi anemia 30 (FA) pathway involved primarily in the repair of cisplatin-induced DNA crosslinks. However, the 31 mechanism by which HPV E6 and E7 attenuate the FA pathway is poorly understood. We demonstrate 32 that E6/E7 expression disrupts crosslink repair and increase cisplatin sensitivity, and attenuate the FA recombination, and translesion synthesis to repair ICLs (8). Once DNA is repaired, the FA pathway is 71 turned off by de-ubiquitination of the FancD2/ FancI complex to prevent prolonged cell cycle arrest and 72 cell death (10). FancD2/ FancI de-ubiquitination is catalyzed by the ubiquitin-specific protease USP1, in 73 conjunction with UAF1 (USP1-associated factor 1). While monoubiquitination of FancD2 is essential for 74 ICL repair, its deubiquitination by the USP1-UAF1 complex is also critical for a functional FA pathway 75 (10-14). Knockout of either USP1 or UAF1 in mice causes an FA-like phenotype (11, 12, 14) and USP1 76 disruption or the absence of de-ubiquitination abrogates FancD2 foci formation and ICL repair and 77 increases sensitivity to DNA cross-linkers (10-13).
78
Several studies have documented an interaction between HPV and the FA pathway. First, loss of FancA 79 or FancD2 lead to hyperproliferation of HPV+ hyperplasia and increased proliferation of HPV genomes 80 in organotypic cultures (15, 16) . Loss of FancD2 potentiates E7 driven cancers of the female lower 81 reproductive tract, and head and neck in two separate studies using mouse models (17, 18) . Second, FA 82 patients are susceptible to oral and anogenital squamous cell carcinomas (19) , though the involvement of 83 HPV in these cancers is controversial because of inconsistent detection of HPV DNA (20-23). Third, 84 HPV+ head and neck cancer cell lines show greater sensitivity to cisplatin compared to HPV negative 85 cells (24).
86
The molecular mechanism(s) by which HPV interacts with the FA pathway is not well-understood. HR-87 HPV (mainly E7) was shown to upregulate several FA genes and activate the FA pathway by increasing 88 FancD2 monoubiquitination and foci formation (25) (26) (27) . In contrast, HPV oncogenes were reported to 89 perturb the functions of several FA proteins, including ATR, BRCA2/FancD1, BRCA1/FancS, and 90 Rad51/FancR (3, (28) (29) (30) 
102
HPV16 oncogenes impair ICL repair and depend on the FA pathway for cisplatin sensitivity
103
We have previously shown that β-HPV 5/8 E6 and HPV16 E6 expression increases sensitivity to 104 crosslinking agents such as cisplatin, mitomycin C and UVB (28). To determine if the expression of E7 105 could also increase crosslinker sensitivity, we expressed HPV16 E6 and E7 individually or together in 106 primary human foreskin keratinocytes (HFKs). Expression of HPV16 E6 and E7 was confirmed by qRT-114 immunoblotting. FancD2 knockdown in LXSN control cells resulted in further increased sensitization to 115 cisplatin, whereas there was little/no effect on cisplatin sensitivity in E6 or E7 expressing cells ( Fig 1C) .
116
These results suggest that cisplatin sensitivity of HPV oncogene expressing cells is due to a defect in the 117 FA pathway, particularly at or downstream of FancD2.
118
The ability of E6/E7 expressing cells to repair cisplatin-induced ICLs was investigated by utilizing a 119 modified comet assay which has been widely used to evaluate ICL repair in vivo at the single cell level (32) (33) (34) . Cells were treated with cisplatin for 2 hr and then incubated in cisplatin-free medium. At 24, 48 121 and 72 hours post-treatment, cells were harvested and frozen to analyze all samples concurrently. Cells
120

122
were thawed and irradiated immediately prior to the comet assay, to deliver a fixed level of random DSBs 123 (Fig 2A) . Crosslinks hold the two strands of DNA together during alkaline denaturation and retard 124 electrophoretic mobility of the irradiated DNA resulting in reduced tail moment compared to untreated 125 irradiated controls. The tail moment was at a basal level in untreated and unirradiated cells ( Fig 2B) . At 0 126 hr post-cisplatin treatment, the tail moment was decreased in all cell types compared to corresponding 127 irradiated untreated controls. At 72 hr post-cisplatin treatment, LXSN cells regained the tail moment 128 indicating that these cells were able to repair crosslinks. In contrast, E6E7 expressing cells did not 129 improve the tail moment 72 hr after cisplatin treatment, suggesting that ICLs remained unrepaired in these 130 cells ( Fig 2C) . Further, repair kinetics of cisplatin-induced ICLs were expressed as the percentage of 139 FancD2/ FancI monoubiquitination is not impaired by HPV oncogenes
140
To screen for defects in the FA pathway, we first examined the levels of FancD2 in HPV oncogene 141 expressing cells. When untreated cells were analyzed, total FancD2 (Ub + non-Ub) levels were 142 significantly increased in E6/E7 expressing cells compared to LXSN control ( Fig 3A) . When E6 or E7
143
were individually expressed, cells had about 2 times more total FancD2 compared to LXSN; but the level 144 increased by ~4 fold when E6 and E7 were expressed together. Total FancI (Ub + non-Ub) levels were 145 also proportionately increased in E6/E7 expressing cells compared to LXSN.
146
FancD2 monoubiquitination was evaluated in E6/E7 expressing cells as a readout to define an activated 147 FA pathway. Ub-FancD2 or Ub-FancI can be distinguished from the non-Ub form as a retarded mobility 148 on gels. E6 and E7 increased FancD2 and FancI monoubiquitination both at baseline and after cisplatin 149 treatment ( Fig 3A) . Approximately a 3-fold increase in the Ub-FancD2: non-Ub FancD2 ratio was 150 observed in E6/E7 expressing cells on cisplatin treatment. Similar results were observed following MMC 151 treatment and UVB irradiation ( Fig S2C-D) . When cells were analyzed following different lengths of 152 cisplatin treatment, LXSN cells showed Ub-FancD2 after 6 hr of cisplatin treatment; but Ub-FancD2 was 153 found in E6 cells even without cisplatin treatment ( Fig S2E) . Further, we performed cellular fractionation 154 analyses and prepared chromatin and soluble fractions from HFKs expressing HPV oncogenes or LXSN 155 control. As expected, Ub-FancD2 or Ub-FancI was enriched dramatically in the chromatin-bound fraction 156 of all transduced HFK cells. Importantly, an increased recruitment of Ub-FancD2/ FancI to chromatin was 157 detected in E6 expressing cells compared to LXSN control and E7 expressing cells ( Fig 3B) .
158
We next sought to know the effectors that may contribute to increasing FancD2 monoubiquitination in 
167
PCNA, and UHFR1 levels were increased in E6 expressing cells compared to LXSN following cisplatin 168 treatment ( Fig 3C) . These results suggest that elevated p-S556 FancI, Ub-PCNA and UHRF1 levels may 169 be involved in the increased chromatin-bound fraction of Ub-FancD2 in E6 cells.
170
HPV oncogenes do not disrupt FancD2 nuclear foci formation but impair colocalization of FancD2 with 171 double-strand DNA breaks
172
To further investigate the interaction of HPV with the FA pathway, the ability of E6/E7 expressing cells 173 to form nuclear foci of FancD2 was quantified as the percentage of cells with >5 FancD2 foci in HFKs.
174
FancD2 foci formation in cisplatin-treated E6 or E7 cells was elevated compared to LXSN controls ( Fig   175  4A-B ). Even without cisplatin treatment, there was increased FancD2 foci formation in E6 expressing 176 cells. Phospho-H2AX foci were used as markers for DNA double-strand breaks (DSB).
177
We previously reported that HPV oncogene expressing cells impair the colocalization of Rad51 with 178 pH2AX (3). The same approach was used to investigate whether E6/E7 expressing cells affect the 179 localization of FancD2 to DSBs. Initial experiments suggested that the expression of HPV oncogenes may 180 cause FancD2 to be localized away from DSBs (as shown by white arrows in cisplatin-treated HFKs 181 transduced with E6/E7, Fig 4A) . However, mislocalization was difficult to quantitate in the nucleus with 182 the numerous DSBs induced by cisplatin. For this, we utilized U2OS-DR cells transduced with LXSN,
183
E6, E7 and E6E7 and transiently transfected with an I-SceI expression vector, as previously described (3).
184
These U2OS cells have clonally integrated DR-GFP cassette consisting of two copies of nonfunctional 185 GFP ( Fig 4C) (41). Exogenous expression of I-SceI produces a single DSB within the first GFP gene 186 which contains an I-SceI recognition site. Thus, cells with single large pH2AX foci were selected and 187 inspected for its colocalization with FancD2 ( Fig 4C) . An excellent colocalization of FancD2 with 188 pH2AX was observed in LXSN cells, but there was ~50% and 20% reduction in colocalization of FancD2 189 in E6 and E7 expressing cells, respectively compared to LXSN cells ( Fig 4D- Rad51 in cisplatin treated HFK LXSN control cells ( Fig S3) . We previously reported that the 199 colocalization of Rad51 with DSB is impaired in E6 expressing cells (3). To determine whether the 200 mislocalization of Rad51 observed in E6 expressing cells is epistatic to FancD2, the Isce-I colocalization 201 assay was repeated, as described above ( Fig 4C) , in FancD2-depleted cells and immunostained with 202 Rad51 and pH2AX. Western blot analysis confirmed FancD2 protein depletion in the siFancD2-
203
transfected cells compared to siControl cells ( Fig 4F) . FancD2 depletion in LXSN cells caused a 204 significant reduction in colocalization of Rad51 to pH2AX in I-SceI induced DSB ( Fig 4G-H) , supporting 205 the idea that FancD2 promotes Rad51 recruitment to DSB in normal cells. However, there was no 206 significant reduction in the % Rad51 colocalization in FancD2 depleted E6 expressing cells, suggesting 207 that the Rad51 recruitment defect associated with E6 cells is due to FancD2 and therefore cannot be 208 reduced further with siFancD2.
210
HPV E6 causes delayed de-ubiquitination of FancD2
211
To further screen for defects in the FA pathway, we investigated how E6/E7 affects the de-ubiquitination 212 pattern of FancD2/ FancI upon DNA repair. Though FancD2/ FancI monoubiquitination is considered as 213 a functional activator of the FA pathway, de-ubiquitination of FancD2/ FancI is also critical for effective 214 ICL repair (10-13). Since E6/E7 increases monoubiquitination of FancD2/ FancI, there may be a defect in 215 de-ubiquitination. To address this, cells were treated with cisplatin or exposed to UV and allowed to 216 recover for the indicated time ( Fig 5A) . Delayed de-ubiquitination of FancD2 was observed in E6 217 expressing cells during recovery after UVB exposure or cisplatin removal ( Fig 5A-C) . Most of FancD2
218 was de-ubiquitinated following 24 hr of UVB and cisplatin release in LXSN cells but not in E6 or E6+E7 219 expressing cells. E7 expressing cells behaved more like LXSN.
220
As Ub-FancD2 persists abnormally in E6 cells, a series of experiments were designed to determine the 221 basis of the delay in de-ubiquitination. First, we asked whether this phenotype was a consequence of 222 decreased levels of the FancD2 deubiquitinating enzyme, USP1. In fact, the opposite result was obtained:
223
E6/E7 expressing cells showed elevated USP1 with cisplatin treatment, while basal levels of USP1 did 224 not differ among untreated cells ( Fig 5D) . These results suggest that delayed FancD2 
237
Third, while FancI phosphorylation at Serine 556 promotes FANCD2 monoubiquitination, its 238 phosphorylation at Serine 565 inhibits FANCD2 de-ubiquitination and impairs ICL repair (7). Therefore,
239
we investigated whether delayed de-ubiquitination of FancD2 was also due to elevated levels of 240 phosphorylated-S565 FancI in E6 expressing cells. As expected, E6 or E6+E7 expressing cells showed 241 increased p-S565 FancI on cisplatin treatment ( Fig 5F) . As phosphorylation of FancI occurs through the 242 ATR-mediated pathway (7) and ATR/CHK1 activation increases FancD2 monoubiquitination (9), 243 delayed FancD2 deubiquitination in E6 cells may be due to persistently activated ATR. Therefore, we 244 examined the levels of p-ATR, p-S345 CHK1, p-S565 FancI as well as FancD2 monoubiquitination/ 245 deubiquitination patterns in cells which had recovered for 24 hr in normal media after cisplatin 246 withdrawal. In E6 or E6+E7 expressing cells, ATR/CHK1 was activated and persisted following cisplatin 247 withdrawal, compared to LXSN ( Fig 5G) . These results are consistent with persistent levels of both 248 ubiquitinated FancD2 and S565-phosphorylated FancI in E6 expressing cells following cisplatin release.
249
Further, persistence of pATR and pCHK1 foci following UV exposure was seen in E6 cells compared to 250 LXSN (data not shown). These data demonstrate that persistent activated ATR/pCHK1/pFancI signaling 251 could contribute to the delayed de-ubiquitination of FancD2 in E6 cells. Fig 5H shows the potential 252 mechanisms for delayed de-ubiquitination of FancD2 in E6 cells.
253
E6 does not abrogate the cell-cycle specific process of FancD2 monoubiquitination or de-ubiquitination
254
To determine whether the effect of E6 on increased monoubiquitination and delayed de-ubiquitination of
255
FancD2 was a consequence of aberrant cell cycle progression, LXSN and E6 cells were synchronized in 256 early S-phase by double-thymidine block, released, and FancD2 mono-or de-ubiquitination patterns were 257 examined as cells progressed through the cell cycle ( Fig 6) . A previous study reported that FancD2 6D) . These data suggest 264 that E6 does not abrogate cell cycle-specific process of FancD2 monoubiquitination and de-265 ubiquitination.
266
E6 mediated increased FancD2 monoubiquitination is p53 independent
267
To further address the regulation of FancD2 mono or de-ubiquitination, the potential role of p53 was 268 examined. The p53 tumor suppressor is a major cellular target of HPV16 E6. One study reported that p53 269 downregulates FancD2 mRNA and protein levels (46). As E6 degrades p53, we expected to see increased
270
FancD2 mRNA and protein levels in E6 expressing cells. However, no significant differences in FancD2 271 mRNA levels between LXSN and E6 cells were observed (data not shown). But, since there was 272 increased protein levels of total FancD2 in E6 expressing cells ( Fig 3A) , we hypothesized that this 273 phenotype was dependent on the ability of E6 to degrade p53. To test this, HFK cells expressing a mutant 274 of HPV16 E6 (8S/9A/10T) that is incapable of degrading p53 (47, 48) was used. Western blot analysis 275 confirmed that E6 expression degrades p53, but the mutant failed to induce p53 degradation ( Fig 7A) .
276
Both cell lines were also evaluated for E6 expression by RT-PCR (data not shown). Total FancD2 level 277 was similar in mutant E6 and wild-type E6 cells ( Fig 7B) 
286
Ub is p53-independent but dependent on p21, its downstream target (49). In our study, although E6
287 showed increased Ub-FancD2 compared to LXSN, this increment was similar in mutant E6 cells, which 288 fail to degrade p53 ( Fig 7B) . Hence, increased monoubiquitination of FancD2 by E6 is not a direct 289 consequence of p53 degradation. To confirm these results, we used p53 knockdown LXSN cells and 290 found that the Ub-FancD2 level was unchanged when compared to p53-sufficient LXSN (Fig S4) .
291
E6 mediated delayed FancD2 de-ubiquitination is dependent on p53 degradation
292
The exact role of p53 in FancD2 de-ubiquitination is not well-understood, although a study reported that 293 p21, a p53 downstream target, represses USP1 transcription (49). Since E6 increased USP1 protein 294 expression on cisplatin treatment (Fig 5D) , we argued that the mechanism by which E6 causes delayed
295
FancD2 de-ubiquitination may be related to its effects on p53 degradation. To examine this, we 296 performed similar experiments as in Fig 4A in cells expressing the mutated E6 that is incapable of 297 degrading p53. At 48hr after UV exposure, FancD2 de-ubiquitination pattern in mutant E6 was similar to 298 LXSN control cells ( Fig 7D, lanes 3 and 9) . Similarly, after 24hr release from cisplatin treatment, mutant 299 E6 showed de-ubiquitinated FancD2 (Ub: Non-Ub ratio of 0.67), whereas wild-type E6 cells had 300 predominately monoubiquitinated FancD2 (ratio of 1.7) ( Fig 7E) . This indicates that delayed FancD2 de-301 ubiquitination in E6 cells was related to the ability to degrade p53. To confirm that the observed effects 302 were specific consequences of p53 degradation, we used shRNA to stably knockdown p53 in LXSN cells 303 and analyzed FancD2 Ub/de-Ub pattern upon UV exposure or cisplatin withdrawal. Once again, FancD2 304 de-ubiquitination was markedly delayed in the absence of p53 ( Fig S5B) . These results strongly support a 305 p53-dependent effect of E6 in causing delayed FancD2 de-ubiquitination.
306
We next examined whether p53 dependent delayed FancD2 deubiquitination in E6 cells is due to 307 activated ATR/CHK1/pFancI signaling. pATR/pCHK1 levels were reduced in cells expressing mutant E6 308 that cannot degrade p53 compared to wild-type E6 cells ( Fig S5C) . Reduction in ATR activity resulted in 309 decreased phosphorylation of FancI at S565 and increased FancD2 de-ubiquitination in mutant E6 cells. (3). To determine whether the abundance of any other downstream protein is affected by HPV oncogenes, 317 the levels of Palb2 were measured. Palb2 level was reduced when E6 was expressed separately or 318 together with E7 ( Fig 8A) . Depleted Palb2 level in E6 cells was not a consequence of p53 degradation 319 ( Fig S6) . Because E6 reduced Palb2 levels, the ability of Palb2 to form nuclear foci in response to 320 cisplatin was examined. In LXSN control cells, the percentage of cells with >5 Palb2 foci peaked at about 321 90% following cisplatin treatment. In contrast, significantly fewer (~60%) E6 expressing HFKs formed
322
Palb2 foci on cisplatin treatment ( Fig 8B) . Although fewer Palb2 foci were observed in E6 cells, these 323 foci perfectly localize to pH2AX in I-SceI transfected U2OS-DR system ( Fig S7A) . Because E6 reduces
324
Palb2 expression and foci formation, and Palb2 is also a component of FA nuclear foci for ICL repair, we 325 asked whether the cisplatin hypersensitivity observed in E6 expressing cells is due to a defect in Palb2.
326
Genetic epistasis analysis for cisplatin sensitivity was conducted by knocking down Palb2. Palb2 327 depletion in LXSN and E7 cells resulted in further sensitization to cisplatin ( Fig 8C) , whereas there was 328 no effect on cisplatin sensitivity in E6 and E6+E7 expressing cells. These results suggest that cisplatin 329 sensitivity seen in E6 expressing cells is, in part, due to a defect in Palb2 expression and foci formation.
330
Reduced Palb2 expression and foci formation in E6 cells ( Fig 8A-B) HPV oncogenes attenuate the FA pathway and contribute to tumorigenicity and the response to cisplatin 345 therapies in HPV-associated malignancies. Our present study (Fig 1) along with others (24) confirm the 346 cross-linker hypersensitivity in HPV oncogene expressing cells. We also show that E6/E7 expressing 347 cells have a defect in repairing cisplatin-induced ICLs (Fig 2) . The epistatic analysis confirmed that ICL 348 sensitivity in E6/E7 cells was due to a defect in FancD2 or downstream of FancD2 (Fig 1) . However,
349
FancD2 monoubiquitination and foci formation were increased in E6 or E7 cells (Fig 3-4) , which is 350 consistent with the previous work conducted in HPV+ and HPV oncogene expressing cells (27, 31) .
351
Strikingly, Ub-FancD2 was seen without cisplatin treatment in E6 expressing cells, which might be due to 352 the presence of activated ATR which increases FancD2 monoubiquitination (9). HPV oncogenes though,
353
promoted the initiation of FA pathway by increasing FancD2 monoubiquitination and foci formation but 354 hindered the completion of the repair by multiple mechanisms. E6 or E7 caused the accumulation of 355 monoubiquitinated FancD2 at sites away from DNA damage. This subsequently hindered the recruitment 356 of downstream protein Rad51 to DNA damage sites in E6 cells (Fig 4D-H) . Further, E6 mediated p53 357 degradation does not hamper cell cycle specific process of FancD2 modifications but abrogate the repair 358 by delaying FancD2 de-ubiquitination ( Fig 5-7) . In addition, E6 reduced the expression and foci 359 formation of Palb2 (Fig 8) . Though there was a defect in FancD2 localization to DSBs in E6 cells, no 360 mislocalization of Palb2 was observed, which is in support of a recent study reporting that FancD2 and
362
HPVs have been shown to recruit numerous cellular repair factors to their replication centers, mainly for 363 HPV amplification (59-61). We speculate that increased Ub-FancD2 and foci formation may create an 364 environment where FA repair proteins are readily available to support HPV replication. Consistent with 365 our speculation, a study showed that higher levels of FancD2 and larger foci are predominantly recruited 366 to HPV DNA rather than cellular genomes and localize to viral replication centers (31). The preferential 
371
This would attenuate ICL repair regardless of the presence or absence of the viral genome because 372 FancD2 helps in the recruitment of downstream FA repair proteins, including Rad51 in nuclear foci at the 373 site of DNA damage. This is supported by our data demonstrating that mislocalized FancD2 in E6 cells 374 causes a reduction in Rad51 recruitment to DSBs (Fig 4G-H) .
375
FancD2 monoubiquitination is necessary for ICL repair, but, by itself, is not sufficient for an efficient FA 376 pathway. In other words, having more monoubiquitinated FancD2 within a cell does not necessarily 377 improve ICL repair. This is exemplified by studies demonstrating that USP1-mediated FancD2 de-378 ubiquitination is required for both FancD2 foci formation and ICL sensitivity (10, 13) and for a functional 379 FA pathway (7, 12, 45) . HPV E6 caused the delayed de-ubiquitination of FancD2, impairing ICL repair 380 ( Fig 5) . HPV E6 cells showed increased phosphorylated S565 FancI and persistently activated 381 ATR/CHK-1, which may, in part, cause delayed FancD2 de-ubiquitination in these cells. inhibits FancD2 de-ubiquitination (7). Augmented ATR activity in E6 expressing cells resulted in 391 increased phosphorylation of FancI at both sites S556 and S565. Increased p-S556 FancI promotes the 392 monoubiquitination of FancD2, but at the same time elevated p-S565 FancI inhibits de-ubiquitination.
393
Together, we provide a mechanistic framework for HR-HPV oncogenes disruption of the FA DNA repair 394 pathway ( Fig S8) . This study advances our understanding of HPV tumorigenesis as well as tumor 395 sensitivity to cisplatin during chemotherapy. Our study suggests a general model for the progression of 
400
An extremely high incidence of cancer in FA patients (68) further suggest that the inactivation of FA 401 pathway results in tumor progression.
402
Our work also has important therapeutic implications. Because continued expression of HPV oncogenes 403 is required for cancer development, most HPV-associated tumors likely have defective FA pathway.
404
These defects result in cisplatin hypersensitivity and demonstrate the mechanisms underlying the 405 therapeutic efficacy of cisplatin in HPV-associated cancers. This also explains the reason underlying the 406 better response rates of HPV+ oropharyngeal cancers than HPV negative head and neck cancers to 407 cisplatin treatment. We believe that tumors that are cisplatin resistant, may have adapted other unexplored 408 mechanisms to escape these defects. One possibility is that some cells with an intact FA pathway are 409 positively selected during cancer progression, resulting in the growth of a cisplatin-resistant tumor.
411
EXPERIMENTAL PROCEDUTES
412
Ethics Statement: The use of deidentified neonatal human foreskins for the study was approved by the 413 Institutional Review Board at the Swedish Medical Center (Seattle, WA).
414
Cell Culture, transduction, and treatment: Primary human foreskin keratinocytes (HFKs) were generated 415 from deidentified neonatal human foreskins and grown in EpiLife Medium supplemented with 60 μM 416 calcium chloride (ThermoFisher Scientific, MEPI500CA) and human keratinocyte growth supplement 417 (ThermoFisher Scientific, S0015). HFKs derived from multiple donors were used to repeat the results.
418
U2OS DR-GFP cells (a gift from Maria Jasin) were grown in DMEM supplemented with 10% FBS.
419
U2OS DR-GFP cells contain a single integrated copy of the DR-GFP cassette (69).
420
Retrovirues were produced in 293T cells (Thermo Fisher Scientific) using plasmid constructs (LTR/VSV-
421
G, CMV/tat, pJK3 and pLXSN vector-empty, E6, E7 or E6E7, or E6 8S/9A/10T mutant) and TransIT- with lentiviral stock in media containing 10ug/ml polybrene. Following 48 hr of transduction, stably 428 transduced cells were selected in 0.5 ug/ml puromycin and the efficiency of knockdown was monitored 429 using immunoblot to p53.
430
Cells were treated with cisplatin (Selleck Chemicals, S1166), Mitomycin C (MMC) (Sigma, M4287), where Cp.IR = mean tail moment of cisplatin-treated and irradiated cells; Ø = mean tail moment of 537 untreated and unirradiated cells, and IR = mean tail moment of irradiated and untreated cells.
538
The data were expressed as the percentage of ICLs that remained at a specific time point where 0 hr was 539 normalized to 100%.
540
Cell-cycle synchronization and analysis: Cells were synchronized at G1/S phase boundary by double-541 thymidine block and cell pellets were harvested for immunoblotting and flow cytometry analysis as 542 described previously (4, 73), with some modifications. Briefly, HFK cells were treated with 2 mM 543 thymidine (Sigma-Aldrich) in EpiLife media without growth supplements for 16 hours. Cells were then 544 washed twice with PBS and released/grown in thymidine-free complete EpiLife media for 9 hours.
545
Thereafter, cells were treated again with 2 mM thymidine in growth supplement-free EpiLife media for 546 another 16 hours. Cells were washed twice with PBS and then released in complete media and harvested 547 every 3 hours after release. Synchronized cells were analyzed at different time points by immunoblotting 548 and analyzing DNA content by DAPI staining. Approximately 10,000 cells were analyzed using flow 549 cytometry (BD FACS-Canto II), and flow histograms were generated using FlowJo software.
550
Statistics: All statistical analyses were done using Student's t-test (Unpaired two-tailed) in GraphPad 551 Prism. P value < 0.05 was considered significant. Statistical significance at P < 0.05, P < 0.01 and P < 552 0.001 are indicated as *, **, ***, respectively. 553 554 ACKNOWLEDGMENTS:
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